NCT05359354View on ClinicalTrials.gov

Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors

NARecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Solid Tumor
Interventions
BIOLOGICAL

Personalized neoantigen tumor vaccine

Biological: neoantigen tumor vaccine with or without PD-1 In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with PD-1

Trial Locations (1)

Unknown

RECRUITING

Peking Union Medical College Hospital, Beijing

Sponsors

Collaborators (1)

NeoCura
All Listed Sponsors
collaborator

NeoCura

INDUSTRY

lead

YueJuan Cheng

OTHER

NCT05359354 - Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter